Welcome to our dedicated page for Revium Recovery SEC filings (Ticker: RVRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Revium Rx (RVRC) SEC filings page brings together the company’s registration statements and related disclosures filed with the U.S. Securities and Exchange Commission. Revium Rx, formerly Revium Recovery Inc., has submitted an S‑1 registration statement and subsequent S‑1/A amendments describing a self-underwritten initial public offering of units and a concurrent resale registration for existing stockholders.
In these filings, Revium Rx outlines its status as a Nevada corporation, an emerging growth company, and a smaller reporting company. The S‑1/A documents describe the structure of the offering, including units composed of common stock and common stock purchase warrants, and a separate resale prospectus covering shares held by selling stockholders and shares issuable upon exercise of investor warrants. The filings also discuss the quotation and trading of the company’s common stock on an OTC Markets tier under the symbol RVRC, as well as the intended application for quotation on a higher OTC marketplace or listing on a national securities exchange, while noting that such outcomes cannot be assured.
For investors analyzing RVRC, the SEC filings provide information on the company’s business description as a preclinical-stage biotechnology company focused on lipid-based and nanoparticle-formulated therapeutics, its risk factors, and the terms of its securities. The registration statements explain that the primary offering is conducted on a best‑efforts basis with no minimum, and that the company will not receive proceeds from resale transactions by selling stockholders, other than potential warrant exercise proceeds.
On Stock Titan, these filings are presented with tools that help users navigate registration statements and amendments, understand the distinction between the primary offering and resale prospectus, and monitor updates as new documents are filed with EDGAR. This allows users to review how Revium Rx describes its business, capital structure, and offering mechanics directly in its official SEC documents.
Revium Rx filed Amendment No. 5 to its Form S-1 registration statement as an exhibits-only update. The company states that this amendment consists of the facing page, an explanatory note, the signature page, the exhibits index, and the filed exhibits, while the remainder of the registration statement is unchanged and therefore omitted. The filing also restates that the registrant may delay the registration statement’s effective date through further amendments and includes signatures from senior executives and directors, along with a power of attorney appointing an attorney-in-fact to sign future amendments.
Revium Rx is registering up to 1,562,500 units in a self-underwritten primary offering and up to 37,625,790 shares of common stock for resale by existing stockholders. Each unit is priced at $3.20 and includes two shares of common stock and one warrant exercisable at $2.40 for three years, creating up to 1,562,500 additional shares upon warrant exercise. The company expects about $4.4 million in net proceeds if all units are sold and plans to allocate roughly 70%–80% to developing its lipid-based drug candidates and clinical trials, and 20%–30% to exploring additional indications. Revium Rx had 60,729,100 shares outstanding before the offering. The resale shareholders may sell their 37,625,790 shares at $1.00 per share until an uplisting or national exchange listing, which the company warns could pressure its stock price and make the primary offering less attractive. As a preclinical biotech with a history of losses, the company highlights significant funding needs, extensive scientific, regulatory and IP risks, and additional geopolitical risks tied to its Israeli operations.
Revium Rx is registering up to 1,562,500 Units in a self-underwritten primary offering and up to 37,625,790 shares of common stock for resale by existing stockholders. Each Unit consists of two common shares and one warrant, offered at a fixed price of $3.20 per Unit, with expected net proceeds to the company of about $4.4 million if all Units are sold. Common shares outstanding would rise from 60,729,100 to 63,854,100, excluding shares issuable on new IPO warrants.
The company is a preclinical biotechnology business developing lipid-based drug delivery platforms for antimicrobial resistance, oncology and immunology, built around liposomal and nano-medicine technologies licensed from Hebrew University’s Yissum and acquired via its LipoVation transaction. Revium Rx has a history of losses, expects continued negative cash flow, and will need substantial additional funding beyond this offering.
Key risks include early-stage product candidates with no regulatory approvals, complex and uncertain clinical and regulatory paths, heavy reliance on licensed intellectual property, potential dilution from warrants and resales, penny-stock trading on the OTC market, and operational and geopolitical risks tied to significant R&D activities in Israel and multi-front regional conflict.
Revium Rx (RVRC) filed an amended S-1 registering a self-underwritten primary offering of 1,562,500 Units at a fixed public offering price of $3.20 per Unit (each Unit = two shares + one warrant) and a resale registration for up to 37,625,790 shares by selling stockholders. The Company expects $4,400,000 in net proceeds if all Units sell and no IPO warrants are exercised, and proposes to allocate approximately 55% (~$2.42M) to advance Nano-Mupirocin, 25% (~$1.1M) to Nano-ARB work, and 20% (~$880k) to G&A.
The filing discloses material risks including a history of losses, substantial future funding needs, potential dilution from existing warrants and resale shares, penny-stock trading restrictions, dependence on key officers, IP and regulatory risks for its nanoformulations, and operational exposure from Israeli geopolitical instability. The document also states an existing Non-Clinical Evaluation Agreement with NIAID and exclusive license rights for LPLT vaccine technology, with a SARS-CoV-2 challenge study expected to resume in Q4 2025 and conclude in Q1 2026.